Kevin Tang and Tang Capital Management LLC, a significant shareholder in Boundless Bio, Inc. (NASDAQ:BOLD), recently increased their stake in the biotechnology company through a series of stock purchases totaling $141,864. The purchases come as the stock trades at $2.45, up more than 111% over the past year, though InvestingPro analysis suggests the company remains undervalued with a Fair Value of $3.02. The transactions occurred between July 6 and July 8, 2026.
The reporting owners acquired a total of 57,210 shares of Boundless Bio common stock at prices ranging from $2.46 to $2.49 per share. On July 6, 27,062 shares were bought at a weighted-average price of $2.49, with individual transactions occurring between $2.46 and $2.50. An additional 15,810 shares were acquired on July 7 at a weighted-average price of $2.48, with prices for individual transactions varying from $2.44 to $2.50. The final purchase on July 8 involved 14,338 shares at a weighted-average price of $2.46, with individual transactions ranging from $2.42 to $2.48. The stock currently trades near its 52-week high of $2.79, reflecting a remarkable 87% surge over the past six months. According to InvestingPro Tips, while the company holds more cash than debt on its balance sheet, it is quickly burning through cash—one of 13 additional insights available to subscribers.
Kevin Tang and Tang Capital Management LLC are identified as 10% owners of Boundless Bio. The shares are held indirectly through various entities. Tang Capital Partners, LP ("TCP") holds 618,407 shares, Tang Capital Partners International, LP ("TCPI") holds 843,301 shares, Tang Capital Partners III, Inc. ("TCP III") holds 618,403 shares, and Tang Capital Partners IV, Inc. ("TCP IV") holds 618,407 shares. Kevin Tang serves as the sole manager of Tang Capital Management, LLC, which acts as the general partner for TCP and TCPI. He also holds positions as the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang maintains a pecuniary interest in all shares beneficially held by these entities.Boundless BioFollowAnalyze BOLDIncluded in our AI-picked strategies·Review strategies2.45▼-0.05(-2.00%)Closed·15:59:59·USD2.41▼-0.04(-1.63%)After Hours·19:42:351D1W1M6M1Y5YMaxCreated with Highcharts 11.4.813:3014:0015:0015:3016:0016:3017:3018:0018:3019:0019:302.42.452.5Analyze BOLDFollowing these transactions, the reporting owners collectively hold 2,698,518 shares of Boundless Bio common stock.
In other recent news, Boundless Bio has announced a definitive merger agreement with Serapha Bio, a clinical-stage biotechnology company. This all-stock transaction will result in the merged entity operating under the name Serapha Bio and trading on Nasdaq under the ticker symbol "AATD." Pre-merger Boundless Bio stockholders are expected to own about 3.7% of the combined company, while Serapha Bio stockholders will hold approximately 96.3%. Before the merger closes, Boundless Bio plans to declare a cash dividend of around $44 to $48 million to its pre-merger stockholders.
In addition to the merger, Boundless Bio held its annual meeting where James Christensen, Ph.D., and Jennifer Lew were elected as Class II directors. The company also presented preclinical data on its lead therapy, BBI-940, at a major cancer research conference. Lastly, Boundless Bio has agreed to terminate its San Diego lease early, with a $10 million payment to the landlord as part of the agreement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Is now the time to buy BOLD?ProPicks AI evaluates BOLD every month against thousands of alternatives using 100+ financial metrics.It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could BOLD be next—or is there a better opportunity in the same space?Don't wait to find out.July Sale - 60% Off InvestingPro